IndieBio / SOSV
IndieBio / SOSV is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at IndieBio / SOSV.
IndieBio / SOSV is a company.
Key people at IndieBio / SOSV.
IndieBio is not a standalone company but SOSV's flagship accelerator program for early-stage biotech startups, focusing on deep tech innovations in human and planetary health.[1][2][3] SOSV, its parent venture capital firm, manages $1.5 billion in assets and invests from pre-seed through later stages, with a mission to fund visionary founders tackling profound challenges in climate and health via programs like IndieBio (life sciences) and HAX (hard tech).[3][5] IndieBio's investment philosophy emphasizes the "too early" stage—backing ideas from paper plans with no prior science—offering up to $525,000 initially (for 8% equity), world-class labs in San Francisco and New York, a 4-6 month intensive program, and long-term support, with 80% of capital deployed post-program and participation in most follow-on rounds.[1][2][8] It has accelerated hundreds of startups, contributing to $9B+ in portfolio value, $8.3B+ raised, and strong ecosystem impact through alumni networks and demo days reaching global investors.[1][4][5]
SOSV was founded in 1995 by Sean O’Sullivan, a serial entrepreneur and philanthropist serving as managing general partner.[1][3] The firm evolved from early tech investments to deep tech specialization, launching IndieBio in 2014 as its first biotech accelerator in San Francisco, followed by IndieBio NY in 2020 (backed by $25M from New York partners) and an expanded SF office in San Francisco's Dogpatch in late 2023.[3][8] Key milestones include SOSV's fundraises: $277M Fund IV (2020), $100M Select Fund (2021), and record $306M SOSV V (April 2024), enabling scaled pre-seed bets (60 annually up to $550K) and 150+ follow-ons yearly.[3][5][6] IndieBio's focus sharpened on life sciences like therapeutics, diagnostics, ag/food tech, and materials, building on SOSV's global network and facilities.[2][3]
IndieBio/SOSV rides the deep tech boom in biotech and climate, where venture shifted toward high-risk, high-impact innovations amid global pressures like health crises and net-zero goals.[1][3][5] Timing aligns with maturing tools (e.g., AI-driven discovery, synthetic biology) lowering barriers for pre-science ideas, enabling faster iteration in a market projected to grow as planetary health demands scale.[2][4] Favorable forces include government backing (e.g., NY's $25M for IndieBio) and LP interest in impact funds, positioning SOSV as the "most active deep tech investor" with 1,000+ co-investors.[3][5][7] They influence the ecosystem by de-risking "first checks," fostering alumni clusters (e.g., second-time founders), and bridging labs to markets, amplifying biotech's role in therapeutics, food systems, and decarbonization.[1][4][6]
IndieBio/SOSV will deepen pre-seed dominance amid AI-biotech convergence and climate urgency, leveraging $1.5B AUM and new facilities to fund 60+ startups yearly while expanding follow-ons via SOSV V.[3][5] Trends like regulatory tailwinds for cell/ag tech and cross-border Asia plays will shape growth, potentially evolving their influence toward syndicate leadership in $10B+ portfolios.[5][7] As deep tech matures, expect more unicorns from their network, reinforcing their role as the go-to for founders too early for others—proving the power of betting on paper plans.[1]
Key people at IndieBio / SOSV.
